Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 47Cisplatin 24Cetuximab 23Paclitaxel 18Nivolumab 18Radiotherapy 15Docetaxel 15Carboplatin 14Fluorouracil 11tremelimumab 7durvalumab 7Erlotinib Hydrochloride 6avelumab 5Radiotherapy, Intensity-Modulated 5Radiosurgery 5Pemetrexed 4Ipilimumab 4Immunoglobulin G 4Gemcitabine 4Fulvestrant 4Capecitabine 4Bevacizumab 4epacadostat 3cemiplimab 3atezolizumab 3Taxes 3Radiation 3Everolimus 3Cyclophosphamide 3Amifostine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Squamous Cell Carcinoma of Head and Neck × tisotumab vedotin × Clear all
NCT02001623 2021-12-29

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

Phase 1/2 Completed
195 enrolled 51 charts
GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡